Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Transforming growth factors.

A B Roberts1, M B Sporn

  • 1Laboratory of Chemoprevention, National Cancer Institute, Bethesda, Maryland 20892.

Cancer Surveys
|January 1, 1985
PubMed
Summary
This summary is machine-generated.

Transforming growth factors (TGFs) are peptides that alter cell behavior. Two types, alpha and beta, differ in structure, receptor binding, and effects on cell growth, with potential therapeutic implications for cancer.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cardioprotective actions of transforming growth factor-β.

Trends in cardiovascular medicine·2011
Same author

Functional redundancy of TGF-beta family type I receptors and receptor-Smads in mediating anti-Mullerian hormone-induced Mullerian duct regression in the mouse.

Biology of reproduction·2008
Same author

Smad3 deficiency inhibits v-ras-induced transformation by suppression of JNK MAPK signaling and increased farnesyl transferase inhibition.

Oncogene·2007
Same author

Targeted mutagenesis of Smad1 reveals an essential role in chorioallantoic fusion.

Developmental biology·2002
Same author

Meeting report: signaling schemes for TGF-beta.

Science's STKE : signal transduction knowledge environment·2001
Same author

Suppressor and oncogenic roles of transforming growth factor-beta and its signaling pathways in tumorigenesis.

Advances in cancer research·2001
Same journal

Future directions: bladder cancer.

Cancer surveys·2004
Same journal

Radiotherapy and chemotherapy for invasive bladder cancer.

Cancer surveys·2004
Same journal

The role of surgery in the multimodality treatment of bladder cancer.

Cancer surveys·2004
Same journal

Clonal development of bladder cancer and its relevance to the clinical potential of HLA antigen and TP53 based gene therapy.

Cancer surveys·2004
Same journal

Clinical evaluation of immunotherapy: are there differences between papillary and flat in situ bladder cancer?

Cancer surveys·2004
Same journal

Molecular biological changes in bladder cancer.

Cancer surveys·2004
See all related articles

Area of Science:

  • Cell Biology
  • Molecular Biology
  • Biochemistry

Background:

  • Transforming growth factor (TGF) is a term for peptides inducing a transformed phenotype in cells.
  • Two distinct classes, Type alpha and Type beta TGFs, have been identified and purified.

Purpose of the Study:

  • To chemically and biologically distinguish between Type alpha and Type beta TGFs.
  • To explore the distinct activities and interactions of these TGF types on cell growth.

Main Methods:

  • Purification of Type alpha and Type beta TGFs to homogeneity.
  • Analysis of amino acid sequences and structural characteristics.
  • Assessment of biological activities on fibroblastic indicator cells in vitro.

Main Results:

Related Experiment Videos

  • Type alpha TGFs are single-chain peptides homologous to epidermal growth factor, competing for receptor binding and typically mitogenic for fibroblasts.
  • Type beta TGFs are homodimeric with unique receptors, exhibiting bifunctional growth effects (stimulation or inhibition) depending on conditions.
  • Interactions between Type alpha and beta TGFs can be synergistic or antagonistic.

Conclusions:

  • Type alpha and beta TGFs possess distinct chemical and biological properties.
  • Understanding TGF interactions may offer therapeutic strategies for malignancy, with Type alpha antagonists potentially treating cancer and Type beta TGFs inhibiting tumorigenesis.